To study the effectiveness of Homoeopathic Medicine in Fifty Millesimal Potency in The Management fungal infection Among Adults

Effectiveness of Individualized Homoeopathic Medicine in Fifty Millesimal Potency in The Management of Tinea Corporis Among Adults an Experimental Non Controlled Study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096249

Enrollment

Registered

2025-10-21

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis

Interventions

Intervention1: Homoeopathic management: Homoeopathic management with individualized homoeopathic medicine in fifty millesimal potency Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Patients of adult age group Clinically diagnosed patients of Tinea corporis Patients of all genders Patients willing to give their free consent

Exclusion criteria

Exclusion criteria: Complication of Tinea corporis like secondary bacterial infection,eczema ,Majocchi granuloma Cases having Tinea corporis infection secondary to Autoimmune disease Cases of immuno-compromised diseases Pregnant and lactating female patients under any line of treatment for Tinea corporis for last3 months Cases whose pretreatment DASI score is above 41.

Design outcomes

Primary

Measure	Time frame
Outcome assessment will be done by applying Dermatophytosis Area Severity Index score A DASI score of 1 to 15 is Considered Mild disease. 2. A DASI score of 16 to 40 is Considered Moderate disease 3.A DASI score of more than 41 is Consider Severe disease. Timepoint: Duration of study is 18 months. Duration of each case Each case will be studied for a period of 6 months or if remission occur, whichever is earlier. Duration of Follow up is Each case will be followed up at the interval of 15 days or as and when required. Clinical assessment will be done at baseline, 3rd month and at the end of the treatment or 6th month, whichever is earlier.	—

Measure

Time frame

Outcome assessment will be done by applying Dermatophytosis Area Severity Index score A DASI score of 1 to 15 is Considered Mild disease. 2. A DASI score of 16 to 40 is Considered Moderate disease 3.A DASI score of more than 41 is Consider Severe disease. Timepoint: Duration of study is 18 months. Duration of each case Each case will be studied for a period of 6 months or if remission occur, whichever is earlier. Duration of Follow up is Each case will be followed up at the interval of 15 days or as and when required. Clinical assessment will be done at baseline, 3rd month and at the end of the treatment or 6th month, whichever is earlier.

—

Secondary

Measure	Time frame
NOT APPLICABLETimepoint: NOT APPLICABLE	—

Countries

India

Contacts

Public ContactDR Sachin Y Chokakkar

Dr G D Pol Foundation Y M T Homoeopathic Medical College and PG Institute Hospital

newbeginingsach@yahoo.com9172488888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026